Compare Eli Lilly And Co (LLY) vs Oxford Lane Capital Corp (OXLC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Oxford Lane Capital Corp — how do they compare? Eli Lilly And Co trades at $1,179.27 (market cap $1.04T), while Oxford Lane Capital Corp trades at $8.56 (market cap $835.71M). The key difference: Eli Lilly And Co is far larger — about 1244.5× Oxford Lane Capital Corp's market cap, and Oxford Lane Capital Corp pays the higher dividend (28.15%). Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and Oxford Lane Capital Corp for 50 Days on average.
| LLY | OXLC | |
|---|---|---|
Market Cap | $1.04T | $835.71M |
Volume | 3,064,878 | 1,125,263 |
Sector | Health | Financials |
52-Week High | $1.28K | $16.66 |
52-Week Low | $799.57 | $8.15 |
Typical Hold Time | 93 Days | 50 Days |
Enterprise Value | $1.09T | $1.23B |
Dividend Yield | 0.59% | 28.15% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,169.93, down 1.58% on the day, but maintains strong bullish momentum with consistent earnings beats and robust revenue growth. The company's weight-loss drug portfolio continues to drive exceptional performance, with Q2 2026 EPS of $8.38 beating expectations by 31%. Technical indicators show bullish moving averages while fundamentals reveal impressive 83.4% gross margins and 102.44% ROE. Recent clinical trial successes for next-generation obesity treatments position Lilly for continued market leadership.
LLY presents a compelling growth story with dominant positioning in the expanding obesity/diabetes market, though elevated valuations (P/E 39.26) and regulatory risks require monitoring. Analyst consensus remains strongly bullish with $1,350 price target representing 15% upside. The primary investment thesis centers on pipeline execution and market expansion opportunities, balanced against competitive pressures and valuation concerns.
OXLC trades at $8.53, up 0.83% today, but faces significant fundamental challenges with a negative ROE of -39.16% and recent earnings misses. Technical indicators show a bearish trend with strong selling pressure on moving averages, though RSI suggests potential oversold conditions. The company maintains a consistent $0.20 monthly dividend while navigating substantial net asset value declines reported in recent updates.
The outlook remains cautious with deteriorating fundamentals offset by high dividend yield. Key risks include unsustainable payout ratios and NAV erosion, while potential upside exists if CLO market conditions stabilize. Analyst sentiment is divided with 50% buy ratings but technicals indicate continued downward pressure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Oxford Lane Capital Corp
Oxford Lane Capital Corp. is a non-diversified, closed-end management investment company. Its primary investment objective is to achieve high current income, with a secondary objective of capital appreciation. The company primarily invests in equity and junior debt tranches of collateralized loan obligations (CLOs), which are pools of corporate loans. OXLC is known for its high-yield distribution policy and provides investors with leveraged exposure to the CLO market.
Read more on OXLC →
